Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.55 Insider Own42.39% Shs Outstand7.23M Perf Week-33.66%
Market Cap9.69M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.17M Perf Month21.82%
Income-12.27M PEG- EPS next Q- Inst Own1.06% Short Float / Ratio2.10% / 0.04 Perf Quarter8.06%
Sales0.74M P/S13.09 EPS this Y- Inst Trans-87.04% Short Interest0.09M Perf Half Y-79.88%
Book/sh2.03 P/B0.66 EPS next Y- ROA-83.66% Target Price20.20 Perf Year-81.86%
Cash/sh0.16 P/C8.14 EPS next 5Y- ROE-142.03% 52W Range0.67 - 18.70 Perf YTD-78.56%
Dividend- P/FCF- EPS past 5Y-7.69% ROI-102.77% 52W High-92.83% Beta0.46
Dividend %- Quick Ratio0.46 Sales past 5Y2020.61% Gross Margin39.31% 52W Low98.84% ATR0.25
Employees23 Current Ratio0.46 Sales Q/Q-62.42% Oper. Margin-1269.91% RSI (14)48.85 Volatility17.28% 15.73%
OptionableNo Debt/Eq0.40 EPS Q/Q28.07% Profit Margin-1659.59% Rel Volume0.20 Prev Close1.26
ShortableYes LT Debt/Eq0.22 EarningsNov 15 BMO Payout- Avg Volume2.50M Price1.34
Recom3.00 SMA20-3.53% SMA5017.87% SMA200-67.48% Volume513,288 Change6.35%
Nov-21-23 08:30AM
Nov-16-23 10:05AM
Nov-15-23 09:00AM
Oct-26-23 08:30AM
Oct-17-23 08:30AM
08:30AM Loading…
Oct-09-23 08:30AM
Aug-23-23 08:30AM
Aug-17-23 09:19AM
Aug-10-23 08:30AM
Aug-07-23 08:30AM
Aug-03-23 09:20AM
Aug-01-23 08:30AM
Jul-31-23 09:30AM
Jul-27-23 09:22AM
Jul-26-23 08:30AM
12:30PM Loading…
Jul-24-23 12:30PM
Jul-06-23 08:30AM
Jun-26-23 08:30AM
Jun-20-23 08:30AM
Jun-12-23 08:30AM
Jun-06-23 08:30AM
May-22-23 08:30AM
May-04-23 08:30AM
Apr-26-23 08:30AM
Apr-10-23 08:30AM
Apr-06-23 08:30AM
Mar-31-23 06:49PM
Mar-20-23 07:00AM
Mar-14-23 07:00AM
Feb-28-23 08:30AM
04:16PM Loading…
Feb-23-23 04:16PM
Feb-21-23 08:30AM
Jan-19-23 08:30AM
Jan-18-23 08:25AM
Jan-05-23 08:30AM
Dec-20-22 11:05AM
Nov-17-22 08:30AM
Nov-14-22 06:20PM
Nov-07-22 08:30AM
Nov-02-22 08:30AM
Oct-05-22 08:30AM
Sep-23-22 08:30AM
Sep-16-22 09:36AM
Sep-13-22 08:30AM
Sep-09-22 08:30AM
Aug-22-22 08:30AM
Aug-18-22 08:30AM
Aug-15-22 05:48PM
Aug-02-22 08:30AM
Jul-18-22 08:30AM
Jul-13-22 08:30AM
Jul-06-22 08:30AM
Jun-30-22 08:30AM
Jun-21-22 08:30AM
Jun-16-22 08:30AM
Jun-10-22 08:30AM
Jun-07-22 01:10PM
Jun-01-22 08:30AM
May-25-22 08:30AM
May-23-22 07:30AM
May-16-22 05:46PM
May-13-22 08:30AM
May-12-22 09:00AM
May-10-22 08:30AM
May-05-22 08:30AM
May-03-22 08:30AM
Apr-28-22 08:30AM
Apr-26-22 08:30AM
Mar-31-22 04:18PM
Mar-23-22 09:25AM
Mar-08-22 06:15AM
Feb-02-22 08:00AM
Jan-05-22 08:30AM
Dec-22-21 08:30AM
Dec-15-21 08:30AM
Dec-10-21 01:38PM
Dec-09-21 08:30AM
Nov-15-21 04:33PM
Nov-11-21 09:00AM
Nov-03-21 11:18AM
Nov-02-21 06:18AM
Nov-01-21 11:32AM
Oct-27-21 08:30AM
Oct-15-21 12:05PM
Oct-12-21 08:30AM
Sep-13-21 08:30AM
Sep-01-21 03:54PM
Aug-30-21 08:30AM
Aug-26-21 08:30AM
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.